Connor, Clark & Lunn Investment Management Ltd. Cytom X Therapeutics, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$20 Billion
Q4 2024

A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 286,480 shares of CTMX stock, worth $194,806. This represents 0.0% of its overall portfolio holdings.

Number of Shares

286,480

Previous 280,593 2.1%

Holding current value

$194,806

Previous $331,000 10.88%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 10, 2025	BUY	$0.86 - $1.29 $5,062 - $7,594	5,887 Added 2.1%	286,480 $295,000
Q3 2024 Nov 08, 2024	BUY	$1.12 - $1.51 $29,537 - $39,823	26,373 Added 10.37%	280,593 $331,000
Q2 2024 Aug 09, 2024	SELL	$1.21 - $5.13 $60,637 - $257,084	-50,114 Reduced 16.47%	254,220 $310,000
Q1 2024 May 09, 2024	BUY	$1.41 - $2.74 $152,017 - $295,410	107,814 Added 54.86%	304,334 $663,000
Q4 2023 Feb 09, 2024	BUY	$1.07 - $1.55 $54,127 - $78,408	50,586 Added 34.66%	196,520 $304,000
Q3 2023 Nov 13, 2023	SELL	$1.26 - $1.87 $12,733 - $18,898	-10,106 Reduced 6.48%	145,934 $188,000
Q2 2023 Aug 10, 2023	BUY	$1.41 - $1.92 $30,640 - $41,723	21,731 Added 16.18%	156,040 $268,000
Q1 2023 May 09, 2023	SELL	$1.48 - $2.88 $24,732 - $48,127	-16,711 Reduced 11.07%	134,309 $202,000
Q4 2022 Feb 10, 2023	SELL	$1.19 - $1.91 $71,018 - $113,986	-59,679 Reduced 28.32%	151,020 $241,000
Q3 2022 Nov 10, 2022	BUY	$1.23 - $1.97 $4,462 - $7,147	3,628 Added 1.75%	210,699 $306,000
Q2 2022 Aug 05, 2022	BUY	$1.53 - $2.89 $10,514 - $19,860	6,872 Added 3.43%	207,071 $379,000
Q1 2022 May 12, 2022	SELL	$2.67 - $4.68 $4,162 - $7,296	-1,559 Reduced 0.77%	200,199 $535,000
Q4 2021 Feb 10, 2022	BUY	$3.87 - $7.39 $568,166 - $1.08 Million	146,813 Added 267.2%	201,758 $874,000
Q3 2021 Nov 12, 2021	BUY	$4.32 - $6.43 $237,362 - $353,296	54,945 New	54,945 $280,000
Q2 2021 Aug 12, 2021	SELL	$6.33 - $9.91 $583,898 - $914,128	-92,243 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$6.6 - $9.0 $222,842 - $303,876	33,764 Added 57.74%	92,243 $713,000
Q4 2020 Feb 16, 2021	BUY	$6.47 - $7.9 $227,045 - $277,226	35,092 Added 150.05%	58,479 $383,000
Q3 2020 Nov 12, 2020	SELL	$6.55 - $8.83 $158,293 - $213,394	-24,167 Reduced 50.82%	23,387 $156,000
Q2 2020 Aug 13, 2020	SELL	$7.4 - $14.64 $384,015 - $759,728	-51,894 Reduced 52.18%	47,554 $396,000
Q1 2020 May 13, 2020	BUY	$3.61 - $8.6 $247,909 - $590,587	68,673 Added 223.15%	99,448 $762,000
Q4 2019 Feb 12, 2020	BUY	$5.17 - $8.91 $159,106 - $274,205	30,775 New	30,775 $256,000
Q3 2017 Nov 14, 2017	SELL	$13.53 - $18.17 $195,508 - $262,556	-14,450 Closed	0 $0
Q2 2017 Aug 14, 2017	BUY	N/A	14,450	14,450 $224,000

Others Institutions Holding CTMX

# of Institutions

Shares Held

46.1M

Call Options Held

3.7K

Put Options Held

4.7K

View Full List

About CytomX Therapeutics, Inc.

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $44.8M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

More about CTMX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account

Connor, Clark & Lunn Investment Management Ltd. Cytom X Therapeutics, Inc. Transaction History